Status:

UNKNOWN

Metabolomic Study in Huntington's Disease (METABO-HD)

Lead Sponsor:

University Hospital, Angers

Conditions:

Huntington Disease

Eligibility:

All Genders

20-70 years

Phase:

NA

Brief Summary

The purpose of this project is to study Huntington's disease by metabolomic approach.

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • For all groups:
  • age between 20 and 70 years
  • signature of the informed consent
  • covered by social security
  • For presymptomatic group:
  • positive genetic test with CAG repeat length ≥ 37 in HTT gene
  • Unified Huntington Disease Rating Scale ≤ 5
  • For symptomatic group:
  • positive genetic test with CAG repeat length ≥ 37 in HTT gene
  • The Unified Huntington's Disease Rating Scale motor score ≥ 6
  • The Total Functional Capacity score ≥ 11
  • Exclusion Criteria for all groups:
  • participation in another therapeutic trial (3 months exclusion period)
  • pregnancy and breastfeeding
  • persons deprived of their liberty by judicial or administrative decision

Exclusion

    Key Trial Info

    Start Date :

    October 9 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 1 2019

    Estimated Enrollment :

    150 Patients enrolled

    Trial Details

    Trial ID

    NCT03296176

    Start Date

    October 9 2017

    End Date

    September 1 2019

    Last Update

    November 1 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    CHU Angers

    Angers, France, 49000